Eculizumab biosimilar by Turgut Ilaclari for Neuromyelitis Optica (Devic’s Syndrome): Likelihood of Approval
Eculizumab biosimilaris under clinical development by Turgut Ilaclari and currently in Phase I for Neuromyelitis Optica (Devic’s Syndrome).
Eculizumab biosimilaris under clinical development by Turgut Ilaclari and currently in Phase I for Neuromyelitis Optica (Devic’s Syndrome).
What's Your Reaction?
